R 28935

Known as: R-28935, erythro-1-(1-(2-(1,4-benzodioxan-2-yl)-2hydroxyethyl)-4-piperidyl)-2-benzimidazolinone 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1975-1980
01219751980

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1980
1980
Prazosin (3 micrograms/kg) infused prior to erythro-1-(1-[2-(1,4-benzodioxan-2-yl)-2-hydroxyethyl]-4-piperidyl)-2… (More)
Is this relevant?
1978
1978
Intravenous administration of erythro-1-(1-[2-(1,4-benzodioxan-2-yl)-2-OH-Et]-4-piperidyl)-2-benzimidazolinone (R-28935) (25--100… (More)
Is this relevant?
1977
1977
Systemic administration of the centrally acting antihypertensive agent R 28935 to cats resulted in a long lasting decrease of… (More)
Is this relevant?
1975
1975
Erythro-1-(1-[2-(1,4-benzodioxan-2-yl)-2-OH-ET]-4-piperidyl)-2-benzimidazolinone (R 28935), provokes marked antihypertensive… (More)
Is this relevant?
1975
1975
In the dog, erythro-1-[2-(1,4benzodioxan-2-yl)-2-OH-ET]-4-piperidyl)-2-benzimidazolinone (R 28935) lowers the blood pressure for… (More)
Is this relevant?